Presentation of HER2 epitopes using a filamentous plant virus-based vaccination platform

Journal of Materials Chemistry B

Volumn 2, Issue 37, 2014, Pages 6249-6258

  Shukla, Sourabh ^a   Wen, Amy M ^a   Commandeur, Ulrich ^b   Steinmetz, Nicole F ^a,c,d  

^a Case Western Reserve University   (United States)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Case Western Reserve University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907075156     PISSN: 20507518     EISSN: 2050750X     Source Type: Journal    
DOI: 10.1039/c4tb00749b     Document Type: Article

References (76)

1. J. S. Ross and J. A. Fletcher, The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy, Oncologist, 1998, 3, 237-252.
2. F. Rilke, M. I. Colnaghi, N. Cascinelli, S. Andreola, M. T. Baldini, R. Bufalino, G. Della Porta, S. Menard, M. A. Pierotti and A. Testori, Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors, Int. J. Cancer, 1991, 49, 44-49.
3. S. Dawood, K. Broglio, A. U. Buzdar, G. N. Hortobagyi and S. H. Giordano, Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review, J. Clin. Oncol., 2010, 28, 92-98.
4. C. A. Harris, R. L. Ward, T. A. Dobbins, A. K. Drew and S. Pearson, The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis, Ann. Oncol., 2011, 22, 1308-1317.
5. A. Valachis, D. Mauri, N. P. Polyzos, G. Chlouverakis, D. Mavroudis and V. Georgoulias, Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2- positive breast cancer: A systematic review and meta-analysis, Breast, 2011, 20, 485-490.
6. G. A. Viani, S. L. Afonso, E. J. Stefano, L. I. De Fendi and F. V. Soares, Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials, BMC Cancer, 2007, 7, 153.
7. M. L. Disis, F. M. Shiota and M. A. Cheever, Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens, Immunology, 1998, 93, 192-199.
8. N. K. Nanda and E. E. Sercarz, Induction of anti-self-immunity to cure cancer, Cell, 1995, 82, 13-17.
9. M. Z. Ladjemi, W. Jacot, T. Chardes, A. Pelegrin and I. Navarro-Teulon, Anti-HER2 vaccines: new prospects for breast cancer therapy, Cancer Immunol. Immunother., 2010, 59, 1295-1312.
10. R. Nahta and F. J. Esteva, Herceptin: mechanisms of action and resistance, Cancer Lett., 2006, 232, 123-138. (Pubitemid 43170962)
11. G. Curigliano, M. Rescigno and A. Goldhirsch, Immunology and breast cancer: therapeutic cancer vaccines, Breast, 2007, 16(suppl. 2), S20-S26.
12. S. A. Rosenberg, J. C. Yang and N. P. Restifo, Cancer immunotherapy: moving beyond current vaccines, Nat. Med., 2004, 10, 909-915.
13. B. Seliger and R. Kiessling, The two sides of HER2/neu: immune escape versus surveillance, Trends Mol. Med., 2013, 19, 677-684.
14. D. J. Morgan, H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll and L. A. Sherman, Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity, J. Immunol., 1998, 160, 643-651. (Pubitemid 28049303)
15. B. Seliger, M. J. Maeurer and S. Ferrone, Antigen-processing machinery breakdown and tumor growth, Immunol. Today, 2000, 21, 455-464.
16. R. A. Clynes, T. L. Towers, L. G. Presta and J. V. Ravetch, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat. Med., 2000, 6, 443-446.
17. A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, T. M. Neri and A. Ardizzoni, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer, J. Clin. Oncol., 2008, 26, 1789-1796.
18. C. Triulzi, S. Vertuani, C. Curcio, A. Antognoli, J. Seibt, G. Akusjarvi, W. Z. Wei, F. Cavallo and R. Kiessling, Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors, Cancer Res., 2010, 70, 7431-7441.
19. V. L. Weiss, T. H. Lee, H. Song, T. S. Kouo, C. M. Black, G. Sgouros, E. M. Jaffee and T. D. Armstrong, Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells, PLoS One, 2012, 7, e31962.
20. M. L. Disis, J. R. Gralow, H. Bernhard, S. L. Hand, W. D. Rubin and M. A. Cheever, Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein, J. Immunol., 1996, 156, 3151-3158.
21. O. Radkevich-Brown, J. Jacob, M. Kershaw and W. Z. Wei, Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice, Cancer Res., 2009, 69, 212-218.
22. A. L. de Cerio, N. Zabalegui, M. Rodriguez-Calvillo, S. Inoges and M. Bendandi, Anti-idiotype antibodies in cancer treatment, Oncogene, 2007, 26, 3594-3602. (Pubitemid 46842706)
23. E. A. Mittendorf, G. E. Peoples and S. E. Singletary, Breast cancer vaccines: promise for the future or pipe dream?, Cancer, 2007, 110, 1677-1686.
24. A. Saha and S. K. Chatterjee, Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice, Cell. Immunol., 2010, 263, 9-21.
25. A. Dols, S. L. Meijer, H. M. Hu, V. Goodell, M. L. Disis, S. Von Mensdorff-Pouilly, R. Verheijen, W. G. Alvord, J. W. Smith 2nd, W. J. Urba and B. A. Fox, Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells, J. Immunother., 2003, 26, 163-170. (Pubitemid 36292787)
26. E. A. Mittendorf, J. P. Holmes, S. Ponniah and G. E. Peoples, The E75 HER2/neu peptide vaccine, Cancer Immunol. Immunother., 2008, 57, 1511-1521.
27. G. E. Peoples, P. S. Goedegebuure, R. Smith, D. C. Linehan, I. Yoshino and T. J. Eberlein, Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide, Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 432-436.
28. E. A. Mittendorf, C. E. Storrer, R. J. Foley, K. Harris, Y. Jama, C. D. Shriver, S. Ponniah and G. E. Peoples, Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial, Cancer, 2006, 106, 2309-2317. (Pubitemid 43787653)
29. M. L. Disis, K. Schiffman, K. Guthrie, L. G. Salazar, K. L. Knutson, V. Goodell, C. dela Rosa and M. A. Cheever, Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine, J. Clin. Oncol., 2004, 22, 1916-1925. (Pubitemid 41095184)
30. Y. L. Yip, G. Smith, J. Koch, S. Dubel and R. L. Ward, Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design, J. Immunol., 2001, 166, 5271-5278. (Pubitemid 32280745)
31. N. K. Dakappagari, D. B. Douglas, P. L. Triozzi, V. C. Stevens and P. T. Kaumaya, Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine, Cancer Res., 2000, 60, 3782-3789.
32. N. K. Dakappagari, J. Pyles, R. Parihar, W. E. Carson, D. C. Young and P. T. Kaumaya, A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses, J. Immunol., 2003, 170, 4242-4253. (Pubitemid 36428191)
33. J. Jasinska, S. Wagner, C. Radauer, R. Sedivy, T. Brodowicz, C. Wiltschke, H. Breiteneder, H. Pehamberger, O. Scheiner, U. Wiedermann and C. C. Zielinski, Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu, Int. J. Cancer, 2003, 107, 976-983. (Pubitemid 37429840)
34. M. L. De Temmerman, J. Rejman, J. Demeester, D. J. Irvine, B. Gander and S. C. De Smedt, Particulate vaccines: on the quest for optimal delivery and immune response, Drug Discovery Today, 2011, 16, 569-582.
35. V. W. Bramwell and Y. Perrie, Particulate delivery systems for vaccines: what can we expect?, J. Pharm. Pharmacol., 2006, 58, 717-728. (Pubitemid 43836159)
36. Y. Krishnamachari and A. K. Salem, Innovative strategies for co-delivering antigens and CpG oligonucleotides, Adv. Drug Delivery Rev., 2009, 61, 205-217.
37. J. P. Ridge, F. Di Rosa and P. Matzinger, A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell, Nature, 1998, 393, 474-478.
38. S. W. Howland and K. D. Wittrup, Antigen release kinetics in the phagosome are critical to cross-presentation effi ciency, J. Immunol., 2008, 180, 1576-1583.
39. R. Audran, K. Peter, J. Dannull, Y. Men, E. Scandella, M. Groettrup, B. Gander and G. Corradin, Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro, Vaccine, 2003, 21, 1250-1255. (Pubitemid 36139957)
40. H. Shen, A. L. Ackerman, V. Cody, A. Giodini, E. R. Hinson, P. Cresswell, R. L. Edelson, W. M. Saltzman and D. J. Hanlon, Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles, Immunology, 2006, 117, 78-88.
41. A. Jegerlehner, A. Tissot, F. Lechner, P. Sebbel, I. Erdmann, T. Kundig, T. Bachi, T. Storni, G. Jennings, P. Pumpens, W. A. Renner and M. F. Bachmann, A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses, Vaccine, 2002, 20, 3104-3112.
42. M. C. Canizares, L. Nicholson and G. P. Lomonossoff, Use of viral vectors for vaccine production in plants, Immunol. Cell Biol., 2005, 83, 263-270. (Pubitemid 40799554)
43. C. Marusic, P. Rizza, L. Lattanzi, C. Mancini, M. Spada, F. Belardelli, E. Benvenuto and I. Capone, Chimeric Plant Virus Particles as Immunogens for Inducing Murine and Human Immune Responses against Human Immunodeficiency Virus Type 1, J. Virol., 2001, 75, 8434-8439. (Pubitemid 32768947)
44. K. Uhde-Holzem, V. Schlosser, S. Viazov, R. Fischer and U. Commandeur, Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9, J. Virol. Methods, 2010, 166, 12-20.
45. F. R. Brennan, T. D. Jones, M. Longstaff, S. Chapman, T. Bellaby, H. Smith, F. Xu, W. D. Hamilton and J. I. Flock, Immunogenicity of peptides derived from a fibronectin-binding protein of S. aureus expressed on two different plant viruses, Vaccine, 1999, 17, 1846-1857. (Pubitemid 29172353)
46. C. Lico, C. Mancini, P. Italiani, C. Betti, D. Boraschi, E. Benvenuto and S. Baschieri, Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice, Vaccine, 2009, 27, 5069-5076.
47. S. Massa, P. Simeone, A. Muller, E. Benvenuto, A. Venuti and R. Franconi, Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein, Hum. Gene Ther., 2008, 19, 354-364. (Pubitemid 351591427)
48. S. Wagner, J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C. Zielinski and U. Wiedermann, Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice, Breast Cancer Res. Treat., 2007, 106, 29-38. (Pubitemid 47498086)
49. U. Wiedermann, A. B. Davis and C. C. Zielinski, Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines, Breast Cancer Res. Treat., 2013, 138, 1-12.
50. U. Wiedermann, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen, E. Garner-Spitzer, R. Bartsch, G. Steger, H. Pehamberger, O. Scheiner and C. C. Zielinski, A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study, Breast Cancer Res. Treat., 2009, 119, 673-683.
51. K. L. Lee, K. Uhde-Holzem, R. Fischer, U. Commandeur and N. F. Steinmetz, Genetic engineering and chemical conjugation of potato virus X., Methods Mol. Biol., 2014, 1108, 3-21.
52. N. F. Steinmetz, M. E. Mertens, R. E. Taurog, J. E. Johnson, U. Commandeur, R. Fischer and M. Manchester, Potato virus X as a novel platform for potential biomedical applications, Nano Lett., 2010, 10, 305-312.
53. K. M. Kim, E. Y. Shin, J. H. Moon, T. H. Heo, J. Y. Lee, Y. Chung, Y. J. Lee, H. M. Cho, S. U. Shin and C. Y. Kang, Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen, Int. J. Cancer, 2002, 102, 428-434. (Pubitemid 35265885)
54. C. I. Spiridon, M. A. Ghetie, J. Uhr, R. Marches, J. L. Li, G. L. Shen and E. S. Vitetta, Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo, Clin. Cancer Res., 2002, 8, 1720-1730. (Pubitemid 34633727)
55. Y. P. Chuan, T. Rivera-Hernandez, N. Wibowo, N. K. Connors, Y. Wu, F. K. Hughes, L. H. Lua and A. P. Middelberg, Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine, Biotechnol. Bioeng., 2013, 110, 2343-2351.
56. M. De Filette, W. Martens, K. Roose, T. Deroo, F. Vervalle, M. Bentahir, J. Vandekerckhove, W. Fiers and X. Saelens, An influenza A vaccine based on tetrameric ectodomain of matrix protein 2, J. Biol. Chem., 2008, 283, 11382-11387.
57. A. Jegerlehner, M. Wiesel, K. Dietmeier, F. Zabel, D. Gatto, P. Saudan and M. F. Bachmann, Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies, Vaccine, 2010, 28, 5503-5512.
58. K. Uhde-Holzem, V. Schlosser, S. Viazov, R. Fischer and U. Commandeur, Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9, J. Virol. Methods, 2010, 166, 12-20.
59. M. F. Bachmann, U. H. Rohrer, T. M. Kundig, K. Burki, H. Hengartner and R. M. Zinkernagel, The influence of antigen organization on B cell responsiveness, Science, 1993, 262, 1448-1451. (Pubitemid 24035067)
60. S. T. Reddy, A. J. van der Vlies, E. Simeoni, V. Angeli, G. J. Randolph, C. P. O'Neil, L. K. Lee, M. A. Swartz and J. A. Hubbell, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat. Biotechnol., 2007, 25, 1159-1164. (Pubitemid 47538111)
61. M. F. Bachmann and G. T. Jennings, Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nat. Rev. Immunol., 2010, 10, 787-796.
62. M. F. Bachmann and R. M. Zinkernagel, Neutralizing antiviral B cell responses, Annu. Rev. Immunol., 1997, 15, 235-270.
63. M. R. Thompson, J. J. Kaminski, E. A. Kurt-Jones and K. A. Fitzgerald, Pattern recognition receptors and the innate immune response to viral infection, Viruses, 2011, 3, 920-940.
64. S. Chekhun, N. Bezdenezhnykh, J. Shvets and N. Lukianova, Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype, Exp. Oncol., 2013, 35, 174-179.
65. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich and W. L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 1987, 235, 177-182.
66. C. M. Snapper and W. E. Paul, Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production, Science, 1987, 236, 944-947.
67. S. Pouyanfard, T. Bamdad, H. Hashemi, M. Bandehpour and B. Kazemi, Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles, PLoS One, 2012, 7, e49539.
68. B. S. Thomas, S. Nishikawa, K. Ito, P. Chopra, N. Sharma, D. H. Evans, D. L. Tyrrell, O. F. Bathe and D. E. Rancourt, Peptide vaccination is superior to genetic vaccination using a recombineered bacteriophage lambda subunit vaccine, Vaccine, 2012, 30, 998-1008.
69. S. Shukla, C. Dickmeis, A. S. Nagarajan, R. Fischer, U. Commandeur and N. F. Steinmetz, Molecular farming of fluorescent virus-based nanoparticles for optical imaging in plants, human cells and mouse models, Biomater. Sci., 2014, 2, 784-797.
70. S. S. Cruz, A. G. Roberts, D. A. Prior, S. Chapman and K. J. Oparka, Cell-to-cell and phloem-mediated transport of potato virus X. The role of virions, Plant Cell, 1998, 10, 495-510. (Pubitemid 28542194)
71. J. Tilsner, O. Linnik, M. Louveaux, I. M. Roberts, S. N. Chapman and K. J. Oparka, Replication and trafficking of a plant virus are coupled at the entrances of plasmodesmata, J. Cell Biol., 2013, 201, 981-995.
72. D. Baulcombe, S. Chapman and S. Santa Cruz, Jellyfish green fluorescent protein as a reporter for virus infections, Plant J., 1995, 7, 1045-1053.
73. K. J. Oparka, A. G. Roberts, D. A. M. Prior, S. Chapman, D. Baulcombe and S. Santa Cruz, Imaging the greenfluorescent protein in plants - viruses carrying the torch, Protoplasma, 1996, 189, 133-141.
74. S. S. Cruz, S. Chapman, A. G. Roberts, I. M. Roberts, D. A. Prior and K. J. Oparka, Assembly and movement of a plant virus carrying a green fluorescent protein overcoat, Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 6286-6290. (Pubitemid 26230297)
75. S. Shukla, A. M. Wen, N. R. Ayat, U. Commandeur, R. Gopalkrishnan, A. M. Broome, K. W. Lozada, R. A. Keri and N. F. Steinmetz, Biodistribution and clearance of a filamentous plant virus in healthy and tumor-bearing mice, Nanomedicine, 2014, 9, 221-235.
76. C. S. Rae, I. W. Khor, Q. Wang, G. Destito, M. J. Gonzalez, P. Singh, D. M. Thomas, M. N. Estrada, E. Powell, M. G. Finn and M. Manchester, Systemic trafficking of plant virus nanoparticles in mice via the oral route, Virology, 2005, 343, 224-235. (Pubitemid 41599881)